Dr. Preeti Vyas Post doctoral fellow

Preeti Vyas, PhD, has a broad background in pharmacology, drug discovery, and neuroscience, particularly in epilepsy and developmental research. Her initial research at Daiichi Sankyo included the high-throughput screening of new chemical compounds using translationally sound cell-free and cell-based models. She has received rigorous pre- and postdoctoral training in interpreting behavioral and quantitative video-electroencephalographic changes associated with various models of epilepsy, neurodevelopmental, and sleep disorders. Her foundational expertise was further refined during her initial post-doc at the Michael V. Johnston Center for Developmental Neuroscience at the Kennedy Krieger Institute and Johns Hopkins Neurology, where she broadened her focus to include other models of neurodevelopmental disorders frequently associated with seizures, like Syngap1 haploinsufficiency, CDKL5 deficiency disorders, hypoxic ischemic encephalopathy etc.

Currently, at Kannan lab, she evaluates the translational value of clinically relevant dendrimer nanotherapies using diverse in vitro and in vivo models, including mouse models of temporal lobe epilepsy, Rett syndrome, cerebral palsy, pediatric brain injury, and other rodent models of neuropathic pain. As she embarks on a career in translational neuroscience, her primary focus lies in the drug discovery and development strategies for these disorders. Her goal is to expand her understanding of disease mechanisms in neurological conditions and work towards developing effective interventions, particularly for epilepsy and neurodevelopmental disorders.